

## Triumeq PD (abacavir/dolutegravir/lamivudine) – New formulation approval

- On March 30, 2022, <u>ViiV Healthcare announced</u> the <u>FDA approval</u> of <u>Triumeq</u>
   <u>PD(abacavir/dolutegravir/lamivudine)</u> tablets for oral suspension, for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg.
  - Triumeq PD alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegravir in Triumeq PD is insufficient in these subpopulations.
- Triumeq is also available as an oral tablet.
- Triumeq PD carries a boxed warning for hypersensitivity reactions and exacerbations of hepatitis
  B.
- Triumeq PD is contraindicated in patients:
  - Who have the HLA-B\*5701 allele
  - With prior hypersensitivity reaction to abacavir, dolutegravir, or lamivudine
  - Receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events with concomitant use of dolutegravir
  - With moderate or severe hepatic impairment
- Additional warnings and precautions for Triumeq PD include hepatotoxicity; lactic acidosis and severe hepatomegaly with steatosis; embryo-fetal toxicity; risk of adverse reactions or loss of virologic response due to drug interactions; immune reconstitution syndrome; different formulations are not interchangeable; and myocardial infarction.
- The most common adverse reactions of at least moderate intensity (≥ 2% in those receiving Triumeq) were insomnia, headache, and fatigue.
- Triumeq PD is recommended in pediatric patients weighing 10 kg to less than 25 kg. The dosage varies depending on patient weight. Refer to the drug label for complete dosing instructions for Triumeq PD and dosing for Triumeq.
- ViiV Healthcare launch plans for Triumeq PD are pending. Triumeq PD will be available as a tablet for oral suspension containing 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.